The US Food and Drug Administration wants to make the logistics of being an advisory committee member easier to help attract and keep the experts it needs, Chief Scientist Namandjé Bumpus said.
US FDA Chief Scientist Wants To Make Advisory Committee Participation Easier
Namandjé Bumpus says hybrid panels are the future and stakeholders should not oversimplify coming committee reform into just a voting or non-voting meeting binary.
